Skip to main content

Table 1 Susceptibility of P. aeruginosa (245 isolates) Pathogens to Antimicrobials in the Latin America regiona from the 2018 PACTSb Database

From: Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis

 % Susceptible
 MIC (mg/mL)RangeCLSIcEUCASTc
Antimicrobial agent50%90% %S%I%R%S%I%R
Ceftolozane-tazobactam0.540.12 to > 3290.20.89.090.2 9.8
Amikacin4> 320.5 to > 3283.61.215.279.14.516.4
Ampicillin-sulbactam> 64> 648 to > 64      
Aztreonam8> 160.25 to > 1664.113.522.477.6 22.4
Cefepime2320.25 to > 25680.07.812.280.0 20.0
Ceftazidime2> 320.5 to > 3277.16.116.777.1 22.9
Ceftriaxone> 8> 81 to > 8      
Ciprofloxacin0.12> 16≤0.03 to > 1668.94.526.668.9 31.1
Colistin0.51≤0.06 to 2100.0 0.0100.0 0.0
Doripenem0.58≤0.06 to > 878.47.314.372.26.121.6
Gentamicin2> 16≤0.12 to > 1677.02.020.977.0 23.0
Imipenem1> 8≤0.12 to > 874.33.722.078.0 22.0
Levofloxacin0.5320.03 to > 3264.35.729.964.3 35.7
Meropenem0.516≤0.015 to > 3273.57.818.873.512.214.3
Piperacillin-tazobactam41280.25 to > 12874.312.213.574.3 25.7
Tigecycline8> 81 to > 8      
  1. a Includes only Latin American countries (i.e., Argentina, Brazil, Chile, Costa Rica, Mexico, and Panama) with available data in the PACTS database
  2. bPACTS Program to Assess Ceftolozane/Tazobactam Susceptibility
  3. c Criteria as published by CLSI [2019] and EUCAST [2019]
  4. CLSI Clinical and Laboratory Standards Institute; EUCAST European Committee on Antimicrobial Susceptibility Testing; MIC minimum inhibitory concentration; PACTS Program to Assess Ceftolozane/Tazobactam Susceptibility